Skip to content
POM-V Prescription Required Companion Animal

Purevax RCP FeLV Lyophilisate and Solvent for Suspension for Injection

Active ingredients: Feline calicivirus, Feline leukemia virus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Form

Injection

Species

Cats

Manufacturer

Boehringer Ingelheim Vetmedica GmbH

VMD MA No.

04491/5054

What it's used for

Active immunisation of cats aged 8 weeks and older: - - - - related disease. Onset of immunity: Revised: December 2024 AN: 02040/2024 - primary vaccination...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Feline calicivirus + Feline...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Purevax RCP FeLV Lyophilisate and Solvent for Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Active immunisation of cats aged 8 weeks and older:
-
-
-
-
related disease.
Onset of immunity:

Revised: December 2024
AN: 02040/2024
-
primary vaccination course.
-
Duration of immunity:
-
primary vaccination course and 3 years after the last re-vaccination.
-
None.
Cats:
Common
(1 to 10 animals / 100 animals treated):
Apathy, anorexia, and hyperthermia
.
Injection site reactions (pain, itching,
oedema)
.
Uncommon
(1 to 10 animals / 1 000 animals treated):
Hypersensitivity reaction
. Very rare
(<1 animal / 10 000 animals treated,
including isolated reports):
Emesis
.
lasting usually for 1 or 2 days.
slight pain at palpation, itching or limited oedema disappearing within 1 or 2
weeks at most.

Revised: December 2024
AN: 02040/2024
may require appropriate symptomatic treatment.
mostly within 24 to 48 hours.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder, or its local
representative, or the national competent authority via the national reporting
system. See section “Contact details” of the package leaflet.
Vaccinate healthy animals only.

Special precautions for use in animals:
It is recommended that a test for FeLV antigenaemia be carried out prior to
vaccination.
Vaccination of FeLV positive cats is of no benefit.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show
the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.
Safety and efficacy data are available which demonstrate that this vaccine can
be administered the same day but not mixed with Boehringer Ingelheim
adjuvanted vaccine against rabies.
No information is available on the safety and efficacy of this vaccine when used
with any other veterinary medicinal product except the products mentioned
above. A decision to use this vaccine before or after any other veterinary
medicinal product therefore needs to be made on a case-by-case basis.
Store and transport refrigerated (2 C – 8 C).
Protect from light.
Do not freeze.
Not applicable.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: live feline rhinotracheitis virus + live feline
panleucopenia virus / parvovirus + inactivated feline calicivirus antigen.
ATCvet code: QI06AH09
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline
panleucopenia and feline leukaemia.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus,
feline panleucopenia virus and feline leukaemia virus.
The veterinary medicinal product was shown to reduce excretion of feline
calicivirus at onset of immunity and for one year after vaccination.
The feline leukaemia vaccine strain is a recombinant canarypox virus
expressing the env and gag
group A is infective and immunisation against sub-group A provides full
protection against A, B and C. After inoculation, the virus expresses the
protective proteins, but does not replicate in the cat. As a consequence, the
vaccine induces an immune status against feline leukaemia virus.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.